Regulation of the Mts1-Mts2-Dependentade6-M26 Meiotic Recombination Hot Spot and Developmental Decisions by the Spc1 Mitogen-Activated Protein Kinase of Fission Yeast

ABSTRACT

The M26 meiotic recombination hot spot in the ade6 gene of Schizosaccharomyces pombe is activated by the heterodimeric M26 binding protein Mts1-Mts2. The individual Mts1 (Atf1, Gad7) and Mts2 (Pcr1) proteins are also transcription factors involved in developmental decisions. We report that the Mts proteins are key effectors of at least two distinct classes of developmental decisions regulated by the mitogen-activated protein (MAP) kinase cascade. The first class (osmoregulation, spore viability, and spore quiescence) requires the Spc1 MAP kinase and the Mts1 protein but does not require the Mts2 protein. The second class (mating, meiosis, and recombination hot spot activation) requires the Spc1 kinase and the Mts1-Mts2 heterodimer. Northern and Western blotting eliminated any significant role for the Spc1 kinase in regulating the expression levels of the Mts proteins. Gel mobility shift experiments indicated that the Mts1-Mts2 heterodimer does not need to be phosphorylated to bind to ade6-M26 DNA in vitro. However, in vivo dimethyl sulfate footprinting demonstrated that protein-DNA interaction within cells is dependent upon the Spc1 MAP kinase, which phosphorylates the Mts1 protein. Thus, the Spc1 kinase helps regulate the effector activities of the Mts1-Mts2 heterodimer in part by modulating its ability to occupy the M26 DNA site in vivo. Meiotic recombination hot spot function is likely the result of DNA conformational changes imparted by binding of the Mts1-Mts2 meiotic transcription factor.

ACKNOWLEDGMENTS

We thank Charlie Albright, Jeff Flick, Wallace Sharif, and Ron Wisdom for helpful discussions and Steve Lindsey and Calley Hardin for laboratory assistance.

This work was supported by a grant from the National Institutes of Health (GM54671). M.D.K. was supported in part by a training grant from the National Institutes of Health (CA09582), and W.P.W. was a Leukemia Society of America Special Fellow (3021-94) for a portion of this research.